Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Mojoon vs Signos

Mojoon
Graded #476

Lower grade

vs+8.5
Signos
Graded #294

Higher grade

The verdict

Signos takes it — 61.4/100 to 52.9/100.

Signos grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Signos (Signos+) is a metabolic-health platform that bundles clinician-prescribed compounded GLP-1 (semaglutide) with an FDA-cleared continuous glucose monitor (CGM) and app — pairing the medication with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSignos +14
30
44
Dose & formulationSignos +12
52
64
Clinical oversightSignos +10
74
84
Labs & monitoringSignos +18
53
71
FulfillmentSignos +6
65
71
Contract termsMojoon +35
55
20
Mojoon · left barSignos · right bar

The numbers

MetricMojoonSignos
WeighScore52.9/10061.4/100
GradeCC
Scorecard rank#476#294
Semaglutide$450/mo (starting dose, compounded)$199/mo (6-month plan, compounded)
TirzepatideNot disclosed$199/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Mojoon

Graded #476 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Premium pricing relative to market
Signos

Graded #294 · C

Strengths

  • Bundles compounded GLP-1 (semaglutide) with an FDA-cleared CGM and app — glucose-guided weight loss, not just medication
  • Starting at $199/mo on a 6-month program, with the CGM included at no extra cost
  • Free rapid shipping; HSA/FSA eligible
  • Real-time glucose insights and app coaching to help sustain results after GLP-1

Where it loses points

  • Compounded GLP-1s are not FDA-approved finished products
  • Headline price is a 6-month-program rate, not month-to-month
  • Only semaglutide is shown in the program; tirzepatide availability is not confirmed
  • Compounding pharmacy partner and state availability are not published on the landing page

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard